STOCK TITAN

Sutro Biopharma - STRO STOCK NEWS

Welcome to our dedicated page for Sutro Biopharma news (Ticker: STRO), a resource for investors and traders seeking the latest updates and insights on Sutro Biopharma stock.

Overview of Sutro Biopharma

Sutro Biopharma (NASDAQ: STRO) is a clinical-stage biopharmaceutical company that redefines cancer therapeutic development with its proprietary cell-free protein synthesis platform, XpressCF®. Utilizing innovative antibody drug conjugates (ADCs) and bispecific antibody technologies, the company designs and develops precisely engineered cancer therapeutics with a focus on oncology and autoimmune disorders.

Innovative Technology and Unique Approach

Sutro has pioneered a unique, cell-free discovery and manufacturing process that transcends the limitations of traditional cell-based methods. This approach allows the rapid iterative testing and optimization of molecular candidates within a matter of weeks, ensuring that each therapeutic is finely tuned for safety, potency, and targeted efficacy. The company's state-of-the-art, cGMP cell-free manufacturing facility offers a competitive edge, enabling efficient production at a scale that supports both clinical studies and broader therapeutic development.

Robust Pipeline and Research Initiatives

The company’s pipeline is robust and diverse, including multiple clinical stage candidates that target high unmet needs in cancer treatment. Notable programs revolve around its lead ADC candidate, which is designed to target folate receptor alpha (FRα) expressed on various tumor cells. By leveraging industry collaborations and strategic partnerships, Sutro has advanced its development programs through critical clinical trials, underscoring its commitment to transforming cancer therapy and improving patient outcomes.

Competitive Position and Value Proposition

Sutro Biopharma occupies a unique position within the competitive oncology sector. Its integrated technology platform and early-stage clinical advancements set it apart from companies reliant on traditional methods. The cell-free approach not only shortens development cycles but also reduces the complexities associated with biologics manufacturing, promising potentially higher therapeutic indexes and broader patient benefits. With careful execution of clinical studies and strategic partnerships, the company reinforces its expertise and dedication to delivering precisely designed cancer therapeutics.

Business Model and Operational Strategy

The company generates revenue through its collaborations, licensing agreements, and milestone-driven partnerships with global healthcare organizations. Its business model is anchored in continuous innovation, leveraging a proprietary platform that supports both in-house development and external partnerships. This integrated strategy facilitates the rapid transition from molecule discovery to clinical evaluation, ensuring that therapeutic candidates are developed efficiently and remain at the forefront of emerging cancer treatments.

Key Highlights and Strategic Focus

  • Proprietary Cell-Free Technology: The XpressCF® platform enables rapid molecule discovery and scalable manufacturing without reliance on living cells.
  • Targeted Oncology Therapeutics: Focused on developing ADCs and bispecific antibodies, Sutro is at the cutting edge of precision oncology.
  • Diverse Clinical Pipeline: With multiple candidates in clinical stages, the company addresses various tumor types through innovative therapeutic options.
  • Integrated Business Model: Revenue streams include strategic collaborations and licensing agreements that support sustained innovation and product development.
  • Expertise in Manufacturing: Its exclusive cell-free manufacturing facility underlines its operational excellence and scalability in production.

Overall, Sutro Biopharma’s approach reflects a commitment to transcending traditional biologics methods by enhancing the speed and precision of drug development. Its technology-driven strategy, industry partnerships, and diversified pipeline collectively contribute to a strong foundation in the competitive landscape of oncology therapeutics, positioning the company as a significant player in advancing next-generation cancer treatments.

Rhea-AI Summary

Sutro Biopharma (NASDAQ: STRO), a clinical-stage drug development company, announced CEO Bill Newell will present at three virtual investor conferences in November 2021. The presentations include:

  • Credit Suisse 30th Annual Healthcare Conference: Nov. 10, 2021, 4:20 p.m. EST
  • Stifel Virtual Healthcare Conference: Nov. 15, 2021, 1:20 p.m. EST
  • Jefferies London Healthcare Conference: Nov. 18, 2021, 3:00 a.m. EST

Live webcasts can be accessed via the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.28%
Tags
conferences
-
Rhea-AI Summary

Sutro Biopharma and BioNova Pharmaceuticals have announced an option agreement for the development and commercialization of STRO-001, a CD74-targeting ADC, in Greater China. BioNova will pay Sutro an initial $4 million and potential milestone payments totaling up to $200 million. Sutro maintains global rights outside Greater China. The collaboration aims to address unmet medical needs in hematologic cancers, with BioNova committed to advancing STRO-001 through clinical development and regulatory approval. Sutro will receive tiered royalties based on sales in the region.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.28%
Tags
none
-
Rhea-AI Summary

Sutro Biopharma (NASDAQ: STRO) announced on Sept 30, 2021, an extension of its research term for the cytokine derivative program with Merck for an additional two years, aimed at completing preclinical research for a second candidate. Sutro is eligible for up to $10 million from this extension. The collaboration leverages Sutro's proprietary protein engineering platforms, XpressCF® and XpressCF+™, and has previously resulted in milestone payments of $5 million and $15 million for earlier collaborations. The ongoing research could lead to innovative cancer treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.29%
Tags
none
Rhea-AI Summary

Sutro Biopharma announced on September 15, 2021, that its Compensation Committee granted restricted stock units (RSUs) of 150,000 shares and stock options for 145,000 shares to three new employees. These grants were part of an inducement to join Sutro and comply with Nasdaq rules. The RSUs will vest annually over four years, while stock options will vest annually and monthly thereafter, also over four years. Sutro specializes in developing next-generation cancer therapeutics through its protein engineering platforms, advancing multiple ADC candidates in clinical trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.64%
Tags
none
-
Rhea-AI Summary

Sutro Biopharma (NASDAQ: STRO) announced the addition of two key executives, Nicole M. Chieffo and Werner Rubas, to its leadership team. Chieffo, with over 25 years in clinical operations, previously held senior roles at Janssen Pharmaceuticals, leading to successful drug approvals. Rubas brings 30 years of experience, most recently as Executive Director at Nektar Therapeutics. Chief Medical Officer Arturo Molina and President of Research Trevor Hallam highlighted the expertise these leaders bring to advance Sutro's pipeline. The company focuses on developing cancer therapeutics, including its ADCs STRO-001 and STRO-002.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
management
-
Rhea-AI Summary

Sutro Biopharma (NASDAQ: STRO) announced that CEO Bill Newell will participate in the 2021 Wells Fargo Securities Healthcare Conference via a virtual fireside chat on September 9 at 3:20 p.m. ET. A live webcast will be available on Sutro's website, with archived replays accessible for 30 days post-event.

Sutro specializes in precise protein engineering to develop innovative cancer therapeutics, with candidates like STRO-001 and STRO-002 in clinical trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.04%
Tags
conferences
Rhea-AI Summary

Sutro Biopharma (NASDAQ: STRO) announced that the FDA has granted Fast Track designation for STRO-002, an antibody-drug conjugate targeting the folate receptor alpha, aimed at treating patients with platinum-resistant ovarian cancer. This designation allows for more frequent FDA interactions, potentially accelerating clinical development. Preliminary studies show promising activity and tolerability of STRO-002. The ongoing Phase 1 trial has completed dose escalation, with enrollment in the expansion cohort continuing in the US and Spain.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.43%
Tags
none
-
Rhea-AI Summary

Sutro Biopharma (NASDAQ: STRO) reported its Q2 2021 financial results, showing revenue of $28 million, significantly up from $9.5 million in Q2 2020. Cash and equivalents totaled $283.4 million, down from $326.5 million at year-end 2020, with a runway projected into H2 2023. The company continues to make progress in ADC trials, particularly with STRO-002 for ovarian cancer. Notable partnerships include ongoing collaborations with Merck, Bristol Myers Squibb, and EMD Serono. Operating expenses rose to $37.9 million from $25.9 million year-over-year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
-
Rhea-AI Summary

Sutro Biopharma (NASDAQ: STRO) appointed Jane Chung as Chief Commercial Officer, effective August 9, 2021. With over 20 years in the pharmaceutical sector, including as President of AstraZeneca Canada, Chung will lead Sutro's commercial strategy, focusing on oncology communities as the company progresses its clinical programs, including STRO-001 and STRO-002. Sutro also granted Chung 75,000 restricted stock units and 160,000 stock options under its 2021 Equity Inducement Plan. The company aims to transform cancer treatment using its innovative technologies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
management
Rhea-AI Summary

Sutro Biopharma (NASDAQ: STRO) announced CEO Bill Newell's participation in the panel "ADCs – Take Me to Your Tumor" at the 12th Annual Wedbush PacGrow Healthcare Virtual Conference on August 11, 2021, at 2:20 p.m. ET. A live webcast will be available on the company's website, along with archived replays for 30 days. Sutro focuses on precise protein engineering for next-generation cancer therapies, with candidates like STRO-001 and STRO-002, currently in clinical trials. The company is committed to improving cancer treatments through innovative drug design.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.28%
Tags
conferences

FAQ

What is the current stock price of Sutro Biopharma (STRO)?

The current stock price of Sutro Biopharma (STRO) is $0.5953 as of April 1, 2025.

What is the market cap of Sutro Biopharma (STRO)?

The market cap of Sutro Biopharma (STRO) is approximately 50.0M.

What is Sutro Biopharma's core focus?

Sutro Biopharma primarily focuses on the discovery, development, and manufacturing of next-generation oncology therapeutics using its proprietary cell-free protein synthesis platform.

How does Sutro's technology differ from traditional methods?

Unlike traditional cell-based systems, Sutro uses a cell-free approach that allows for rapid iterative testing and optimization of molecular candidates, thereby shortening development cycles and enhancing drug precision.

What products and therapeutic areas does the company target?

The company targets oncology and autoimmune disorders, with its pipeline centered around antibody drug conjugates (ADCs) and bispecific antibodies designed to deliver targeted cancer treatments.

What role does the XpressCF® platform play in their operations?

The XpressCF® platform underpins both the discovery and manufacturing processes, enabling the design of precisely engineered therapeutics and supporting scalable, efficient production.

How does Sutro Biopharma generate revenue?

Revenue is generated through strategic collaborations, licensing agreements, and milestone-based partnerships, which support ongoing product development and clinical trials.

Who are the likely competitors in this space?

Competitors typically include other biotechnology and pharmaceutical companies that focus on cell-based discovery and manufacturing, though Sutro differentiates itself through its cell-free technology and innovative ADC design.

How does Sutro’s manufacturing capability provide an advantage?

Its exclusive cGMP cell-free manufacturing facility allows for flexible, rapid production of biologics, reducing the time and complexity associated with traditional cell-based manufacturing processes.

What is the significance of its clinical-stage candidates?

The clinical-stage candidates validate Sutro’s innovative approach, demonstrating that the company can advance complex molecules through critical stages of development toward potential therapeutic use.
Sutro Biopharma

Nasdaq:STRO

STRO Rankings

STRO Stock Data

49.96M
80.20M
4.21%
73.99%
5.41%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO